CN1281359A - 应用噻唑烷二酮类药物治疗高血糖症 - Google Patents

应用噻唑烷二酮类药物治疗高血糖症 Download PDF

Info

Publication number: CN1281359A
Authority: CN; China
Prior art keywords: hyperglycemia; insulin sensitizers; plasma glucose; chemical compound; pharmaceutically
Prior art date: 1997-10-13
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Pending

Application number

CN98812083A

Other languages

English (en)

Chinese (zh)

Inventor

R·E·白金汉

S·A·史密斯

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

SmithKline Beecham Ltd

Original Assignee

SmithKline Beecham Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1997-10-13

Filing date

1998-10-12

Publication date

2001-01-24

1998-10-12 Application filed by SmithKline Beecham Ltd filed Critical SmithKline Beecham Ltd

2001-01-24 Publication of CN1281359A publication Critical patent/CN1281359A/zh

Status Pending legal-status Critical Current

Links

201000001421 hyperglycemia Diseases 0.000 title claims abstract description 47
229940123464 Thiazolidinedione Drugs 0.000 title claims description 11
150000001467 thiazolidinediones Chemical class 0.000 title claims description 9
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract description 36
239000008103 glucose Substances 0.000 claims abstract description 36
238000000034 method Methods 0.000 claims abstract description 35
150000001875 compounds Chemical class 0.000 claims description 49
229940122355 Insulin sensitizer Drugs 0.000 claims description 34
239000000203 mixture Substances 0.000 claims description 18
210000002784 stomach Anatomy 0.000 claims description 13
230000003203 everyday effect Effects 0.000 claims description 12
239000003814 drug Substances 0.000 claims description 10
238000002360 preparation method Methods 0.000 claims description 9
150000003839 salts Chemical class 0.000 claims description 8
239000007788 liquid Substances 0.000 claims description 6
238000012360 testing method Methods 0.000 claims description 6
125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
239000012453 solvate Substances 0.000 claims description 5
230000000680 avirulence Effects 0.000 claims description 4
GRVDJDISBSALJP-UHFFFAOYSA-N methyloxidanyl Chemical group [O]C GRVDJDISBSALJP-UHFFFAOYSA-N 0.000 claims description 4
HYAFETHFCAUJAY-UHFFFAOYSA-N pioglitazone Chemical compound N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 HYAFETHFCAUJAY-UHFFFAOYSA-N 0.000 claims description 4
-1 1-methylcyclohexyl Chemical group 0.000 claims description 3
125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 3
239000008194 pharmaceutical composition Substances 0.000 claims description 3
GXPHKUHSUJUWKP-UHFFFAOYSA-N troglitazone Chemical compound C1CC=2C(C)=C(O)C(C)=C(C)C=2OC1(C)COC(C=C1)=CC=C1CC1SC(=O)NC1=O GXPHKUHSUJUWKP-UHFFFAOYSA-N 0.000 claims description 3
229960001641 troglitazone Drugs 0.000 claims description 3
GXPHKUHSUJUWKP-NTKDMRAZSA-N troglitazone Natural products C([C@@]1(OC=2C(C)=C(C(=C(C)C=2CC1)O)C)C)OC(C=C1)=CC=C1C[C@H]1SC(=O)NC1=O GXPHKUHSUJUWKP-NTKDMRAZSA-N 0.000 claims description 3
MVDXXGIBARMXSA-PYUWXLGESA-N 5-[[(2r)-2-benzyl-3,4-dihydro-2h-chromen-6-yl]methyl]-1,3-thiazolidine-2,4-dione Chemical compound S1C(=O)NC(=O)C1CC1=CC=C(O[C@@H](CC=2C=CC=CC=2)CC2)C2=C1 MVDXXGIBARMXSA-PYUWXLGESA-N 0.000 claims description 2
YZFWTZACSRHJQD-UHFFFAOYSA-N ciglitazone Chemical compound C=1C=C(CC2C(NC(=O)S2)=O)C=CC=1OCC1(C)CCCCC1 YZFWTZACSRHJQD-UHFFFAOYSA-N 0.000 claims description 2
229950009226 ciglitazone Drugs 0.000 claims description 2
229950002375 englitazone Drugs 0.000 claims description 2
125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 2
229960005095 pioglitazone Drugs 0.000 claims description 2
NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 abstract description 4
102000004877 Insulin Human genes 0.000 abstract description 2
108090001061 Insulin Proteins 0.000 abstract description 2
229940125396 insulin Drugs 0.000 abstract description 2
241000124008 Mammalia Species 0.000 abstract 1
231100000252 nontoxic Toxicity 0.000 abstract 1
230000003000 nontoxic effect Effects 0.000 abstract 1
231100000489 sensitizer Toxicity 0.000 abstract 1
239000000546 pharmaceutical excipient Substances 0.000 description 8
239000008280 blood Substances 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
206010012601 diabetes mellitus Diseases 0.000 description 6
239000003795 chemical substances by application Substances 0.000 description 5
229940079593 drug Drugs 0.000 description 4
238000002347 injection Methods 0.000 description 4
239000007924 injection Substances 0.000 description 4
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
230000000694 effects Effects 0.000 description 3
230000002641 glycemic effect Effects 0.000 description 3
230000001771 impaired effect Effects 0.000 description 3
239000000600 sorbitol Substances 0.000 description 3
235000010356 sorbitol Nutrition 0.000 description 3
239000006188 syrup Substances 0.000 description 3
235000020357 syrup Nutrition 0.000 description 3
208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
ZOBPZXTWZATXDG-UHFFFAOYSA-N 1,3-thiazolidine-2,4-dione Chemical compound O=C1CSC(=O)N1 ZOBPZXTWZATXDG-UHFFFAOYSA-N 0.000 description 2
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
108010010803 Gelatin Proteins 0.000 description 2
235000010489 acacia gum Nutrition 0.000 description 2
239000001785 acacia senegal l. willd gum Substances 0.000 description 2
125000002015 acyclic group Chemical group 0.000 description 2
230000002421 anti-septic effect Effects 0.000 description 2
239000002775 capsule Substances 0.000 description 2
238000003745 diagnosis Methods 0.000 description 2
238000001647 drug administration Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
239000008273 gelatin Substances 0.000 description 2
229920000159 gelatin Polymers 0.000 description 2
235000019322 gelatine Nutrition 0.000 description 2
235000011852 gelatine desserts Nutrition 0.000 description 2
239000004615 ingredient Substances 0.000 description 2
HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 2
238000004519 manufacturing process Methods 0.000 description 2
239000001267 polyvinylpyrrolidone Substances 0.000 description 2
229920000036 polyvinylpyrrolidone Polymers 0.000 description 2
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 2
239000000843 powder Substances 0.000 description 2
239000000375 suspending agent Substances 0.000 description 2
239000003826 tablet Substances 0.000 description 2
VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
239000000080 wetting agent Substances 0.000 description 2
IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
235000019489 Almond oil Nutrition 0.000 description 1
229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
229920002261 Corn starch Polymers 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 1
239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
206010056997 Impaired fasting glucose Diseases 0.000 description 1
GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
229920000168 Microcrystalline cellulose Polymers 0.000 description 1
241001597008 Nomeidae Species 0.000 description 1
DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
239000000654 additive Substances 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
239000008168 almond oil Substances 0.000 description 1
CEGOLXSVJUTHNZ-UHFFFAOYSA-K aluminium tristearate Chemical compound [Al+3].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CEGOLXSVJUTHNZ-UHFFFAOYSA-K 0.000 description 1
239000003708 ampul Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
239000011230 binding agent Substances 0.000 description 1
239000001506 calcium phosphate Substances 0.000 description 1
229910000389 calcium phosphate Inorganic materials 0.000 description 1
235000011010 calcium phosphates Nutrition 0.000 description 1
229910052799 carbon Inorganic materials 0.000 description 1
125000004432 carbon atom Chemical group C* 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
239000008112 carboxymethyl-cellulose Substances 0.000 description 1
239000003086 colorant Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000008120 corn starch Substances 0.000 description 1
230000001934 delay Effects 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
239000008157 edible vegetable oil Substances 0.000 description 1
239000003995 emulsifying agent Substances 0.000 description 1
239000000839 emulsion Substances 0.000 description 1
238000009505 enteric coating Methods 0.000 description 1
239000002702 enteric coating Substances 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
239000000945 filler Substances 0.000 description 1
238000011049 filling Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
238000007710 freezing Methods 0.000 description 1
239000000499 gel Substances 0.000 description 1
125000005456 glyceride group Chemical group 0.000 description 1
239000008187 granular material Substances 0.000 description 1
239000004519 grease Substances 0.000 description 1
235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
229940071826 hydroxyethyl cellulose Drugs 0.000 description 1
229940102223 injectable solution Drugs 0.000 description 1
239000008101 lactose Substances 0.000 description 1
235000010445 lecithin Nutrition 0.000 description 1
239000000787 lecithin Substances 0.000 description 1
229940067606 lecithin Drugs 0.000 description 1
239000003589 local anesthetic agent Substances 0.000 description 1
239000007937 lozenge Substances 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
235000019359 magnesium stearate Nutrition 0.000 description 1
230000004060 metabolic process Effects 0.000 description 1
FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
229920000609 methyl cellulose Polymers 0.000 description 1
239000001923 methylcellulose Substances 0.000 description 1
235000010981 methylcellulose Nutrition 0.000 description 1
229940016286 microcrystalline cellulose Drugs 0.000 description 1
235000019813 microcrystalline cellulose Nutrition 0.000 description 1
239000008108 microcrystalline cellulose Substances 0.000 description 1
238000002156 mixing Methods 0.000 description 1
238000012986 modification Methods 0.000 description 1
230000004048 modification Effects 0.000 description 1
229940100688 oral solution Drugs 0.000 description 1
238000012856 packing Methods 0.000 description 1
230000002265 prevention Effects 0.000 description 1
125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
239000012744 reinforcing agent Substances 0.000 description 1
238000007789 sealing Methods 0.000 description 1
235000019333 sodium laurylsulphate Nutrition 0.000 description 1
229940079832 sodium starch glycolate Drugs 0.000 description 1
239000008109 sodium starch glycolate Substances 0.000 description 1
229920003109 sodium starch glycolate Polymers 0.000 description 1
239000007787 solid Substances 0.000 description 1
239000000243 solution Substances 0.000 description 1
229940075582 sorbic acid Drugs 0.000 description 1
235000010199 sorbic acid Nutrition 0.000 description 1
239000004334 sorbic acid Substances 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
229940032147 starch Drugs 0.000 description 1
230000001954 sterilising effect Effects 0.000 description 1
238000004659 sterilization and disinfection Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
238000009492 tablet coating Methods 0.000 description 1
239000002700 tablet coating Substances 0.000 description 1
238000002560 therapeutic procedure Methods 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
230000007704 transition Effects 0.000 description 1
QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Diabetes (AREA)
Epidemiology (AREA)
Endocrinology (AREA)
General Chemical & Material Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Hematology (AREA)
Obesity (AREA)
Chemical Kinetics & Catalysis (AREA)
Emergency Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Plural Heterocyclic Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

CN98812083A 1997-10-13 1998-10-12 应用噻唑烷二酮类药物治疗高血糖症 Pending CN1281359A (zh)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GB9721693.1		1997-10-13
GBGB9721693.1A GB9721693D0 (en)	1997-10-13	1997-10-13	Novel treatment

Publications (1)

Publication Number	Publication Date
CN1281359A true CN1281359A (zh)	2001-01-24

Family

ID=10820482

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CN98812083A Pending CN1281359A (zh)	1997-10-13	1998-10-12	应用噻唑烷二酮类药物治疗高血糖症

Country Status (24)

Country	Link
EP (1)	EP1023056A1 (ru)
JP (1)	JP2001519382A (ru)
KR (1)	KR20010024481A (ru)
CN (1)	CN1281359A (ru)
AP (1)	AP2000001787A0 (ru)
AU (1)	AU9547098A (ru)
BG (1)	BG104404A (ru)
BR (1)	BR9815219A (ru)
CA (1)	CA2306086A1 (ru)
CZ (1)	CZ20001297A3 (ru)
EA (1)	EA002659B1 (ru)
GB (1)	GB9721693D0 (ru)
HR (1)	HRP20000255A2 (ru)
HU (1)	HUP0003922A3 (ru)
ID (1)	ID24521A (ru)
IL (1)	IL135513A0 (ru)
NO (1)	NO20001898L (ru)
NZ (1)	NZ503862A (ru)
OA (1)	OA11683A (ru)
PL (1)	PL339813A1 (ru)
SK (1)	SK5312000A3 (ru)
TR (1)	TR200000958T2 (ru)
WO (1)	WO1999018943A1 (ru)
YU (1)	YU28800A (ru)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7045519B2 (en)	1998-06-19	2006-05-16	Chiron Corporation	Inhibitors of glycogen synthase kinase 3

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
ES2137915T3 (es) *	1987-09-04	2000-01-01	Beecham Group Plc	Derivados de tiazolidindiona sustituida.
GB9218830D0 (en) *	1992-09-05	1992-10-21	Smithkline Beecham Plc	Novel compounds
US5478852C1 (en) *	1993-09-15	2001-03-13	Sankyo Co	Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of impaired glucose tolerance in order to prevent or delay the onset of noninsulin-dependent diabetes mellitus

1997
- 1997-10-13 GB GBGB9721693.1A patent/GB9721693D0/en not_active Ceased
1998
- 1998-10-12 CZ CZ20001297A patent/CZ20001297A3/cs unknown
- 1998-10-12 WO PCT/GB1998/003064 patent/WO1999018943A1/en not_active Application Discontinuation
- 1998-10-12 IL IL13551398A patent/IL135513A0/xx unknown
- 1998-10-12 EP EP98949086A patent/EP1023056A1/en not_active Withdrawn
- 1998-10-12 PL PL98339813A patent/PL339813A1/xx unknown
- 1998-10-12 OA OA1200000108A patent/OA11683A/en unknown
- 1998-10-12 NZ NZ503862A patent/NZ503862A/xx unknown
- 1998-10-12 TR TR2000/00958T patent/TR200000958T2/xx unknown
- 1998-10-12 AU AU95470/98A patent/AU9547098A/en not_active Abandoned
- 1998-10-12 YU YU28800A patent/YU28800A/sh unknown
- 1998-10-12 AP APAP/P/2000/001787A patent/AP2000001787A0/en unknown
- 1998-10-12 SK SK531-2000A patent/SK5312000A3/sk unknown
- 1998-10-12 KR KR1020007003934A patent/KR20010024481A/ko not_active Application Discontinuation
- 1998-10-12 ID IDW20000669A patent/ID24521A/id unknown
- 1998-10-12 EA EA200000419A patent/EA002659B1/ru not_active IP Right Cessation
- 1998-10-12 HU HU0003922A patent/HUP0003922A3/hu unknown
- 1998-10-12 JP JP2000515578A patent/JP2001519382A/ja active Pending
- 1998-10-12 CA CA002306086A patent/CA2306086A1/en not_active Abandoned
- 1998-10-12 BR BR9815219-0A patent/BR9815219A/pt not_active Application Discontinuation
- 1998-10-12 CN CN98812083A patent/CN1281359A/zh active Pending
2000
- 2000-04-12 NO NO20001898A patent/NO20001898L/no not_active Application Discontinuation
- 2000-05-02 HR HR20000255A patent/HRP20000255A2/hr not_active Application Discontinuation
- 2000-05-05 BG BG104404A patent/BG104404A/bg unknown

Also Published As

Publication number	Publication date
NO20001898D0 (no)	2000-04-12
EA002659B1 (ru)	2002-08-29
PL339813A1 (en)	2001-01-02
IL135513A0 (en)	2001-05-20
ID24521A (id)	2000-07-20
SK5312000A3 (en)	2000-09-12
NZ503862A (en)	2003-01-31
KR20010024481A (ko)	2001-03-26
CZ20001297A3 (cs)	2001-08-15
BG104404A (bg)	2000-12-29
BR9815219A (pt)	2001-01-02
HRP20000255A2 (en)	2001-02-28
CA2306086A1 (en)	1999-04-22
HUP0003922A2 (hu)	2001-10-28
EP1023056A1 (en)	2000-08-02
YU28800A (sh)	2003-02-28
AU9547098A (en)	1999-05-03
EA200000419A1 (ru)	2000-10-30
TR200000958T2 (tr)	2000-08-21
WO1999018943A1 (en)	1999-04-22
JP2001519382A (ja)	2001-10-23
HUP0003922A3 (en)	2001-12-28
AP2000001787A0 (en)	2000-06-30
GB9721693D0 (en)	1997-12-10
OA11683A (en)	2005-01-12
NO20001898L (no)	2000-06-09

Publication	Publication Date	Title
CN1230171C (zh)	2005-12-07	用噻唑烷二酮和二甲双胍治疗糖尿病
CN1133431C (zh)	2004-01-07	用罗西格列酮和胰岛素治疗糖尿病
CN1264303A (zh)	2000-08-23	用噻唑烷二酮、胰岛素促分泌剂和双胍治疗糖尿病
CN1263467A (zh)	2000-08-16	用噻唑烷二酮、促胰岛素分泌剂和α一葡糖苷酶抑制剂治疗糖尿病
CN1274282A (zh)	2000-11-22	用噻唑烷二酮和α－葡糖苷酶抑制剂治疗糖尿病
UA70302C2 (ru)	2004-10-15	Лечение сахарного диабета тиазолидином и сульфонилмочевиной
CN1281359A (zh)	2001-01-24	应用噻唑烷二酮类药物治疗高血糖症
CN1332638A (zh)	2002-01-23	包含β－激动剂和其它抗糖尿病药物的组合物
CN1281358A (zh)	2001-01-24	噻唑烷二酮在高血糖症治疗中的应用
US20020137773A1 (en)	2002-09-26	Use of thiazolidinediones for the treatment of hyperglycaemia
CN1235586C (zh)	2006-01-11	改进释放组合物及其用途
US20030069283A1 (en)	2003-04-10	Use of thiazolidinediones for the treatment of hyperglycaemia
CN1310619A (zh)	2001-08-29	利用葡萄糖摄入增强剂减小心脏缺血后损伤
AU4586902A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
CN1781483A (zh)	2006-06-07	用噻唑烷二酮和二甲双胍治疗糖尿病
AU4587002A (en)	2002-08-01	Use of thiazolidinediones for the treatment of hyperglycaemia
NZ515554A (en)	2003-09-26	Treatment of diabetes with thiazolidinedione and metformin
MXPA00003634A (en)	2001-05-07	Use of thiazolidinediones for the treatment of hyperglycaemia

Legal Events

Date	Code	Title
2001-01-24	C06	Publication
2001-01-24	PB01	Publication
2001-01-31	C10	Entry into substantive examination
2001-01-31	SE01	Entry into force of request for substantive examination
2005-10-05	C02	Deemed withdrawal of patent application after publication (patent law 2001)
2005-10-05	WD01	Invention patent application deemed withdrawn after publication